杜氏肌营养不良的新兴疗法
杜氏肌营养不良由肌细胞中功能性抗肌萎缩蛋白缺失引起,目前糖皮质激素仍是唯一被明确证实可延缓疾病进展的治疗,尽管长期使用有不良反应。除标准治疗的糖皮质激素外,五种化合物在部分但非全部辖区获批,疗效结果仍待公布;多种早期临床试验有前景的化合物在后期试验未达疗效终点,但许多其他化合物的临床开发正在进行。当前格局因化合物数量多、作用机制多样及基因型特异性适用性而复杂。
要点
- 糖皮质激素仍是唯一被明确证实可延缓杜氏肌营养不良疾病进展的治疗。
- 五种化合物在部分但非全部辖区获批,疗效结果仍待公布。
- 多种早期临床试验有前景的化合物在后期试验未达疗效终点。
核心结论
- 糖皮质激素仍是唯一被明确证实可延缓杜氏肌营养不良疾病进展的治疗,尽管长期使用有不良反应。
主要发现
- 五种化合物在部分但非全部辖区获批,疗效结果仍待公布。
- 多种在早期临床试验中有前景的化合物在后期试验中未达疗效终点。
- 许多其他化合物的临床开发正在进行。
临床怎么用
- 糖皮质激素为杜氏肌营养不良的标准治疗。
局限性
- 杜氏肌营养不良的罕见性和变异性给临床开发带来困难,未来可能通过使用敏感生物标志物、自然史数据和改良的试验设计来克服。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Duchenne muscular dystrophy is an X-linked disease caused by the absence of functional dystrophin in the muscle cells. Major advances have led to the development of gene therapies, tools that induce exon skipping, and other therapeutic approaches, including treatments targeting molecular pathways downstream of the absence of functional dystrophin. However, glucocorticoids remain the only treatment unequivocally shown to slow disease progression, despite the adverse effects associated with their long-term use. Besides glucocorticoids, which are standard care, five compounds have received regulatory approval in some but not all jurisdictions, with further efficacy results being awaited. Several compounds with promising results in early-phase clinical trials have not met their efficacy endpoints in late-phase trials, but the clinical development of many other compounds is ongoing. The current landscape is complicated by the number of compounds in various stages of development, their various mechanisms of action, and their genotype-specific applicability. The difficulties of clinical development that arise from both the rarity and variability of Duchenne muscular dystrophy might be overcome in the future by use of sensitive biomarkers, natural history data, and ameliorated trial designs.
引用
- Markati T, Oskoui M, Farrar MA, et al. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol. 2022. PMID: 35850122. doi:10.1016/S1474-4422(22)00125-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。